SG/CALL/ELI LILLY & CO/400/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 03:35:50 2024-06-14 pm EDT | ||
| 45.91 EUR | -0.15% |
|
| Current month | +15.93% | ||
| 1 month | +31.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 45.91 | -0.15% |
| 24-06-13 | 45.98 | +3.65% |
| 24-06-12 | 44.36 | -0.56% |
| 24-06-11 | 44.61 | +0.86% |
| 24-06-10 | 44.23 | +3.03% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 03:35 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ86XL |
| ISIN | DE000SQ86XL1 |
| Date issued | 2023-02-16 |
| Strike | 400 $ |
| Maturity | 2025-01-17 (215 Days) |
| Parity | 10 : 1 |
| Emission price | 4.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 46.82 € |
|---|---|
| Lowest since issue | 2.88 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant
